# A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection

> **NCT04978337** · PHASE2 · TERMINATED · sponsor: **Janssen Research & Development, LLC** · enrollment: 5 (actual)

## Conditions studied

- Respiratory Syncytial Virus

## Interventions

- **DRUG:** Rilematovir
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04978337
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-17
- **Primary completion:** 2022-03-31
- **Final completion:** 2022-03-31
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Janssen made the strategic decision to discontinue the PRIMROSE study. This decision is not based on any safety concerns.
- **Last updated:** 2024-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04978337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04978337, "A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04978337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*